SCHEMBL26547748

SCHEMBL26547748

Cc1cc2c(O)cc(N3CCOCC3)cc2n(C)c1=O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 6/20 0.44
PIK3CD O00329 2/20 0.42
PIK3CA P42336 2/20 0.42
PIK3CB P42338 2/20 0.42
PIK3CG P48736 2/20 0.42
PIK3C2B O00750 1/20 0.41
MAPT P10636 4/20 0.40
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
LMNA P02545 2/20 0.39
PIK3C3 Q8NEB9 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HTT P42858 1/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
CASP1 P29466 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30480878 1.00 PRKDC (0.44) PRKDCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL30480887 0.82 PIK3CA (0.45) PRKDCPIK3CAMAPTKDM4EALDH1A1
SCHEMBL26547744 0.82 PIK3CA (0.45) PRKDCPIK3CAMAPTKDM4EALDH1A1
SCHEMBL29471257 0.76 PDE1B (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL26112688 0.76 PDE1B (0.38) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL31496156 0.76 GPR119 (0.44) MAPTLMNAALDH1A1MEN1KMT2A
SCHEMBL31426187 0.74 PDE1A (0.32) KDM4EALDH1A1GAAHPGDTSHR
SCHEMBL30480903 0.74 KDM4E (0.34) PIK3CAMAPTKDM4EALDH1A1GAA
SCHEMBL26547751 0.74 KDM4E (0.34) PIK3CAMAPTKDM4EALDH1A1GAA
SCHEMBL24316590 0.72 POLB (0.34) PIK3CALMNAALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322724-A1 HETEROCYCLIC COMPOUNDS AS CBP/EP300 BROMODOMAIN INHIBITORS EP300, HDAC1, BRD3 PRKDC 2786/4885PIK3CD 1559/4885PIK3CA 1790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.